✍ Scribed by Makoto Hiromura; Hiromu Sakurai
No coin nor oath required. For personal study only.
In the 21st century, there has been a dramatic worldwide increase in the prevalence of metabolic syndromes, including diabetes mellitus (DM). Several synthetic pharmaceutical agents have been developed and used for the treatment of type‐2 DM; however, these compounds have several problems such as side effects, hypoglycemia, and weight gain. Therefore, new drugs are required for DM therapy. We have proposed that some vanadyl complexes function as potent insulin‐mimetic and antidiabetic agents in type‐1 and type‐2 DM animal models. In this article, we review the possible action mechanism of insulin‐mimetic and antidiabetic vanadyl complexes, focusing on a recently proposed complex, bis(allixinato)oxovanadium(IV), with respect to the insulin‐signaling pathway in cultured adipocytes.
📜 SIMILAR VOLUMES
Poly-g-glutamic acid (g-PGA) prepared by fermentation of microbe was used as drug carrier for vanadium sulfate to obtain vanadyl-poly-g-glutamic acid (VO-g-PGA) complex. The FI-IR spectrum of the complex demonstrated that the expected VO-g-PGA complex is formed by the coordination of VO 2þ through t
## DOSCH the best affinity from a pool of cells originally activated and expanded by dietary ABBOS (11). However, IDDM is a T cell-mediated disease and it was critical to determine if BSA/ABBOS specific T cells could be detected in IDDM patients. In a collaborative study, now almost completed, of
## Abstract The reaction of 5‐carboalkoxypicolinic acid (5 ROpicH, R=Me, Et, __i__Pr, __s__Bu; 1 a–d) with vanadyl sulfate yielded the complexes [VO(H~2~O)(5 ROpic)~2~], 2 a–d, with H~2~O and one of the picolinato ligands in the equatorial positions, and the second picolinate occupying equatorial (